CD-Venture

Our healthcare system assumes we make decisions based on what is best for us. But it’s not that simple. Everyday stressors often cloud our judgement as to what’s best in the long run. For people with chronic conditions, this can make healthy habit formation difficult. Wellth is a venture-backed digital health company that improves adherence in chronic disease populations. Using the science of behavioral economics—combined with an appreciation for human nature—we uncover and address the unique obstacles that prevent people with chronic conditions from improving patient outcomes. Our program goes beyond current efforts to boost adherence with technology, reminders, and coaching solutions using contingency management and loss aversion to create motivation, behavior change and improve population health at scale. In addition to our RCT-proven outcomes, our easy-to-use mobile platform experience has been proven by health plans, providers, and other organizations to empower members with the incentives and support system they need to establish new healthy habits. Key outcomes for members include improved med and care plan adherence, reduction in readmissions, hospitalizations, and ED utilization, improved PDC, and more. Learn more at www.wellthapp.com.

Our healthcare system assumes we make decisions based on what is best for us. But it’s not that simple. Everyday stressors often cloud our judgement as to what’s best in the long run. For people with chronic conditions, this can make healthy habit formation difficult. Wellth is a venture-backed digital health company that improves adherence in chronic disease populations. Using the science of behavioral economics—combined with an appreciation for human nature—we uncover and address the unique obstacles that prevent people with chronic conditions from improving patient outcomes. Our program goes beyond current efforts to boost adherence with technology, reminders, and coaching solutions using contingency management and loss aversion to create motivation, behavior change and improve population health at scale. In addition to our RCT-proven outcomes, our easy-to-use mobile platform experience has been proven by health plans, providers, and other organizations to empower members with the incentives and support system they need to establish new healthy habits. Key outcomes for members include improved med and care plan adherence, reduction in readmissions, hospitalizations, and ED utilization, improved PDC, and more. Learn more at www.wellthapp.com.

TriOptoTec GmbH develops and markets products and services in the area of photodynamic disinfection and decontamination, using its brand „dyphox“.

leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.

Our healthcare system assumes we make decisions based on what is best for us. But it’s not that simple. Everyday stressors often cloud our judgement as to what’s best in the long run. For people with chronic conditions, this can make healthy habit formation difficult. Wellth is a venture-backed digital health company that improves adherence in chronic disease populations. Using the science of behavioral economics—combined with an appreciation for human nature—we uncover and address the unique obstacles that prevent people with chronic conditions from improving patient outcomes. Our program goes beyond current efforts to boost adherence with technology, reminders, and coaching solutions using contingency management and loss aversion to create motivation, behavior change and improve population health at scale. In addition to our RCT-proven outcomes, our easy-to-use mobile platform experience has been proven by health plans, providers, and other organizations to empower members with the incentives and support system they need to establish new healthy habits. Key outcomes for members include improved med and care plan adherence, reduction in readmissions, hospitalizations, and ED utilization, improved PDC, and more. Learn more at www.wellthapp.com.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Stocard’s mission is to become the #1 mobile wallet in the Western world by making the daily shopping experience easy, engaging and rewarding for it's more than 50 million users. By turning shopper’s phones into their wallet, they’ve simplified the way users are rewarded at their favorite stores and are adding an easy way for their users to get access to financial services on the platform. To date several billion transactions at the point of sale have been facilitiated through Stocard.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Phenex Pharmaceuticals AG was founded in 2002. It is a privately held drug discovery & development company based in the Biotech Cluster Rhine-Neckar with Biology and Chemistry laboratories and offices primarily in Heidelberg and partly in Ludwigshafen. Their company focuses its small-molecule drug discovery expertise in Liver and Gastrointestinal disease areas and has now recently entered the field of Cancer Therapy. They not only devise novel therapeutics for known targets but additionally aim to identify novel molecular mechanisms. This provides the basis for the identification of novel small molecules with "game changing" capabilities. Historically, Phenex has identified two of such novel mechanisms from literature and has translated them into proprietary novel therapeutic small molecules.